Stay updated on Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page footer; no substantive changes to study data, eligibility criteria, or results are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page's revision label updates from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded a Locations section listing Connecticut as a study site and removed the older Connecticut Locations entry and the HHS Vulnerability Disclosure in the prior revision.SummaryDifference0.2%

- Check85 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2 with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedA note clarifying that publications are automatically filled from PubMed was added, and the page revision tag was updated to v3.3.1. The previous PubMed-related note and the older revision tag (v3.2.0) were removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.